{"url_path":"/sec/kapa/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","accession_number":"0001493152-26-022796","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-022796-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":42,"has_tables":true,"body_markdown":"**Item\n5. Other Information.**\n\n \n\nDuring\nthe period ended March 31, 2026, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement”\nor “non-Rule 10b5-1 trading arrangement” (as each item is defined Item 408(a) of Regulation S-K).\n\n \n\n28"}